Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Inclusion criteria:

- Male or female patients aged >=18 years

- Patients with Non Valvular Atrial Fibrillation

- Patient presenting with:

An Acute Coronary Syndrome (ACS) (ST elevation myocardial infarction (STEMI), NonSTEMI
[NSTEMI] or unstable angina [UA]) that was successfully treated by PCI and stenting (either
Bare Metal Stent (BMS) or Drug Eluting Stent) Or Stable Coronary Artery Disease with at
least one lesion eligible for PCI that was successfully treated by elective PCI and
stenting (either BMS or DES)

- The patient must be able to give informed consent in accordance with International
Conference on Harmonisation Good Clinical Practice guidelines and local legislation
and/or regulations.

Exclusion criteria:

- Patients with a mechanical or biological heart valve prosthesis

- Cardiogenic shock during current hospitalisation

- Stroke within 1 month prior to screening visit

- Patients who have had major surgery within the month prior to screening

- Gastrointestinal haemorrhage within one month prior to screening, unless, in the
opinion of the Investigator, the cause has been permanently eliminated

- Major bleeding episode including life-threatening bleeding episode in one month prior
to screening visit

- Anaemia (haemoglobin <10g/dL) or thrombocytopenia including heparin-induced
thrombocytopenia (platelet count <100 x 109/L) at screening

- Severe renal impairment (estimated Creatinine Clearance (CrCl) calculated by
Cockcroft-Gault equation) <30mL/min at screening

- Active liver disease